Here are the Insiders that made it to the Top 5 purchases!
🧵⬇️
1. President and CEO Jacob Chacko acquired 350,000 shares of ORIC Pharmaceuticals $ORIC, a biotech company, paying $4.92 per share for a total amount of $1.72 million. insidearbitrage.com/symbol-metrics…
ORIC Pharmaceuticals $ORIC appointed Jacob Chacko as Chief Executive Officer on May 7, 2018. Prior to this, Jacob was an investor at TPG Capital and he was the CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018.
2. COB and CEO Laurans A. Mendelson acquired 1,200 shares of HEICO Corporation $HEI, an aerospace, defense, and electronic related products company, paying $124.98 per share for a total amount of $149,980. insidearbitrage.com/symbol-metrics…
Mr. Mendelson has over 20 years of successful leadership of $HEI and has served as Heico's Chairman of the Board since December 1990 and has also served as the company's Chief Executive Officer since February 1990.
3. Director David J. Matlin acquired 40,000 shares of Clene $CLNN, a biotech company, paying $2.97 per share for a total amount of $118,600. Mr. Matlin increased his stake by 2.42% to 1,692,749 shares with this purchase. insidearbitrage.com/symbol-metrics…
Mr. Matlin is the Chairman of Clene $CLNN and currently serves on the public boards of MedTech Acquisition Partners $MTAC and U.S. Well Service $USWS, as well as Dermasenso, Pristine Surgical, Traffk, and Empyrean Neuroscience.
4. Director Michael Sileck acquired 17,500 shares of Eastman Kodak Company $KODK, paying $6.45 per share for a total amount of $112,800. insidearbitrage.com/symbol-metrics…
Michael E. Sileck was the COO and CFO of World Wrestling Entertainment from June 2005 to December 2008 and previously served as the CFO of Monster Worldwide from March 2002 to March 2005 and Interactive Corp from September 1999 to February 2002.
5. President and COO Saul B. Rosenthal acquired 13,420 shares of Oxford Square Capital $OXSQ, paying $4.09 per share for a total amount of $54,920. Mr. Rosenthal increased his stake by 0.99% to 1,371,851 shares with this purchase. insidearbitrage.com/symbol-metrics…
Subscribe to receive our free insider weekends articles every Sunday with a summary of the week's top insider purchases and sales: insidearbitrage.com/subscription/
If you found this thread useful, please follow for updates on insider transactions and event-driven situations.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Director Andrew M. Cohn acquired 36,667 shares of $GWRS, paying $16.00 per share for a total amount of $586,672. Mr. Cohn increased his stake by 1.92% to 1.95 million shares with this purchase.
On Nov 9, 2021 Ligand Pharmaceuticals $LGND announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business bit.ly/3JRDSCV